343626-03-9 Usage
Uses
Used in Biochemical Research:
3-(3-Pyridyl)-L-Alanine Hydrochloride is used as a research compound for studying its potential therapeutic effects on neurological disorders and as a chiral building block in the synthesis of organic compounds.
Used in Pharmaceutical Applications:
3-(3-Pyridyl)-L-Alanine Hydrochloride is used as a precursor in the preparation of pharmaceuticals and bioactive molecules, leveraging its unique chemical properties and functional groups.
Used in Chiral Resolution:
3-(3-Pyridyl)-L-Alanine Hydrochloride is used as a chiral resolving agent, playing a crucial role in the separation of enantiomers, which is essential for the development of novel drugs with improved efficacy and reduced side effects.
Used in Drug Development:
3-(3-Pyridyl)-L-Alanine Hydrochloride is employed in the development of novel drugs, where its unique properties and functional groups contribute to the creation of innovative therapeutic agents with potential applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 343626-03-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,3,6,2 and 6 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 343626-03:
(8*3)+(7*4)+(6*3)+(5*6)+(4*2)+(3*6)+(2*0)+(1*3)=129
129 % 10 = 9
So 343626-03-9 is a valid CAS Registry Number.
343626-03-9Relevant academic research and scientific papers
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
